Rapafusyn Pharmaceuticals Raises $28 Million to Revolutionize Drug Discovery with Innovative Molecular Glue Platform
Rapafusyn Pharmaceuticals, a trailblazer in the realm of therapeutic drug discovery, has announced a significant milestone with the closure of a Series A financing round, amassing $28 million. This strategic investment round was led by 3E Bioventures Capital and Proxima Ventures Ltd., with participation from Lapam Capital. Rapafusyn is spearheading the development of non-degrading molecular…
